{"protocolSection": {"identificationModule": {"nctId": "NCT02653482", "orgStudyIdInfo": {"id": "D1690C00032"}, "organization": {"fullName": "Saint Luke's Health System", "class": "OTHER"}, "briefTitle": "Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure", "officialTitle": "Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure", "acronym": "DEFINE-HF"}, "statusModule": {"statusVerifiedDate": "2022-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-03-03", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-06-28", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-06-28", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-01-04", "studyFirstSubmitQcDate": "2016-01-09", "studyFirstPostDateStruct": {"date": "2016-01-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-09-13", "resultsFirstSubmitQcDate": "2021-11-02", "resultsFirstPostDateStruct": {"date": "2021-12-01", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-03-28", "lastUpdatePostDateStruct": {"date": "2022-04-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Saint Luke's Health System", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart failure with reduced systolic function.", "detailedDescription": "A 12-week randomized, double-blind, placebo-controlled trial to evaluate the effects of once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (BNP and NTproBNP), symptoms, health status, and quality of life in patients with chronic heart failure with reduced systolic function."}, "conditionsModule": {"conditions": ["Chronic Heart Failure With Reduced Systolic Function"], "keywords": ["heart failure", "dapagliflozin", "Sodium-glucose co-transporter-2 (SGLT-2) inhibitors"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 263, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dapagliflozin", "type": "ACTIVE_COMPARATOR", "description": "Dapagliflozin 10 mg daily", "interventionNames": ["Drug: Dapagliflozin"]}, {"label": "Dapagliflozin matching placebo", "type": "PLACEBO_COMPARATOR", "description": "Dapagliflozin matching placebo 10 mg daily", "interventionNames": ["Drug: Dapagliflozin matching placebo"]}], "interventions": [{"type": "DRUG", "name": "Dapagliflozin", "armGroupLabels": ["Dapagliflozin"], "otherNames": ["Farxiga"]}, {"type": "DRUG", "name": "Dapagliflozin matching placebo", "armGroupLabels": ["Dapagliflozin matching placebo"], "otherNames": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Difference in the Average of the 6- and 12-week Mean N-terminal Pro B-type Natriuretic Peptide (NTproBNP).", "description": "Difference in the average of the 6- and 12-week mean N-terminal pro B-type natriuretic peptide (NTproBNP).", "timeFrame": "Average of Week 6 and Week 12"}, {"measure": "Percentage of Patients That Achieve a \u2265 5-point Increase in Heart Failure Disease Specific Quality of Life (Assessed Using Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS)) or a \u2265 20% Decrease in NTproBNP Over 12 Weeks", "description": "A composite of the percentage of patients that achieved a meaningful improvement in health status (\u22655-point increase in average of 6- and 12-week KCCQ-OS) or NT-proBNP (\u226520% decrease in average of 6- and 12-week NT-proBNP).\n\nThe KCCQ is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status. For the KCCQ overall summary score, a small but clinically meaningful change is considered to be \u2265 5 points.", "timeFrame": "Average of Week 6 and Week 12"}], "secondaryOutcomes": [{"measure": "Percentage of Patients With a \u2265 5-point Increase in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS)", "description": "Percentage of patients with a \u2265 5-point increase in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) as measured at Week 6 and Week 12.\n\nThe KCCQ is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status. For the KCCQ overall summary score, a small but clinically meaningful change is considered to be \u2265 5 points.", "timeFrame": "Baseline to Week 6 and Week 12"}, {"measure": "Percentage of Patients With a \u2265 20% Decrease in N-terminal Pro B-type Natriuretic Peptide (NTproBNP)", "description": "Percentage of patients with a \u2265 20% decrease in NTproBNP as measured at Week 6 and Week 12.", "timeFrame": "Baseline to Week 6 and Week 12"}, {"measure": "Percentage of Patients With a \u2265 5-point Increase in Kansas City Cardiomyopathy Questionnaire - Overall Summary Score (KCCQ-OS) and a \u2265 20% Decrease in N-terminal Pro B-type Natriuretic Peptide (NTproBNP)", "description": "The KCCQ is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status. For the KCCQ overall summary score, a small but clinically meaningful change is considered to be \u2265 5 points.", "timeFrame": "Average of Week 6 and Week 12"}, {"measure": "Change in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) Over 12 Weeks.", "description": "Change in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) over 12 weeks as measured at Week 6 and Week 12.The KCCQ is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status. For the KCCQ overall summary score, a small but clinically meaningful change is considered to be \u2265 5 points.", "timeFrame": "Baseline to Week 6 and Week 12"}, {"measure": "Change in 6 Minute Walk Score Over 12 Weeks.", "description": "Change in 6 minute walk score over 12 weeks as measured at Week 6 and Week 12. The 6 minute walk test measures the distance in meters that a patient can quickly walk on a flat, hard surface in a period of 6 minutes.", "timeFrame": "Baseline to Week 6 and Week 12"}, {"measure": "Change in Brain Natriuretic Peptide (BNP) Over 12 Weeks.", "description": "Change in BNP over 12 weeks as measured at Week 6 and Week 12 as measured at Week 6 and Week 12.", "timeFrame": "Baseline to Week 6 and Week 12"}, {"measure": "Change in Hemoglobin A1c (HbA1c) Over 12 Weeks.", "description": "Change in HbA1c over 12 weeks as measured at Week 6 and Week 12.", "timeFrame": "Baseline to Week 6 and Week 12"}, {"measure": "Change in Weight Over 12 Weeks", "description": "Change in weight over 12 weeks as measured at Week 6 and Week 12.", "timeFrame": "Baseline to Week 6 and Week 12"}, {"measure": "Change in Systolic Blood Pressure Over 12 Weeks", "description": "Change in systolic blood pressure over 12 weeks as measured at Week 6 and Week 12.", "timeFrame": "Baseline to Week 6 and Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Established diagnosis of New York Heart Association (NYHA) Class II or Class III heart failure (left ventricular ejection fraction \u226440% due to either ischemic or non-ischemic etiology) with reduced systolic function for at least 16 weeks prior to enrollment\n2. No change in diuretic management for at least 1 week prior to enrollment\n3. Brain natriuretic peptide (BNP) \u2265100 pg/mL and/or N-terminal pro b-type natriuretic peptide (NTproBNP) \u2265 400 pg/mL at enrollment\n\nExclusion Criteria:\n\n1. History of type 1 diabetes\n2. Estimated glomerular filtration rate (eGFR) \\< 30 at enrollment\n3. Hospitalization for heart failure within the 30 days prior to enrollment\n4. Admission for an acute coronary syndrome (ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, or unstable angina), percutaneous coronary intervention, or cardiac surgery within the 30 days prior to enrollment\n5. Admission for cardiac resynchronization therapy (CRT) within 90 days prior to the screening visit\n6. Planned cardiovascular revascularization (percutaneous intervention or surgical) or major cardiac surgery (coronary artery bypass grafting, valve replacement, ventricular assist device, cardiac transplantation, or any other surgery requiring thoracotomy) within the 90 days after enrollment\n7. Patients who are volume depleted based upon physical examination at the time of screening or randomization", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "19 Years", "maximumAge": "119 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Mikhail Kosiborod, MD", "affiliation": "Saint Luke's Mid America Heart Institute", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Heart Group of the Eastern Shore", "city": "Fairhope", "state": "Alabama", "zip": "36532", "country": "United States", "geoPoint": {"lat": 30.52297, "lon": -87.90333}}, {"facility": "University of Southern Califiornia", "city": "Los Angeles", "state": "California", "zip": "90032", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "First Coast Cardiovascular Institute", "city": "Jacksonville", "state": "Florida", "zip": "32256", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Charlotte Heart Group Research Center", "city": "Port Charlotte", "state": "Florida", "zip": "33952", "country": "United States", "geoPoint": {"lat": 26.97617, "lon": -82.09064}}, {"facility": "Emory University", "city": "Atlanta", "state": "Georgia", "zip": "30303", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "NorthShore University HealthSystem Research Institute", "city": "Evanston", "state": "Illinois", "zip": "60201", "country": "United States", "geoPoint": {"lat": 42.04114, "lon": -87.69006}}, {"facility": "Northwestern University", "city": "Evanston", "state": "Illinois", "zip": "60208", "country": "United States", "geoPoint": {"lat": 42.04114, "lon": -87.69006}}, {"facility": "Advocate Health and Hospitals", "city": "Oakbrook Terrace", "state": "Illinois", "zip": "60181", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.96451}}, {"facility": "University of Maryland", "city": "Baltimore", "state": "Maryland", "zip": "21201", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Walter Reed National Military Medical Center", "city": "Bethesda", "state": "Maryland", "zip": "20889", "country": "United States", "geoPoint": {"lat": 38.98067, "lon": -77.10026}}, {"facility": "Brigham & Women's Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Henry Ford Health System", "city": "Detroit", "state": "Michigan", "zip": "48202", "country": "United States", "geoPoint": {"lat": 42.33143, "lon": -83.04575}}, {"facility": "Mayo Clinic", "city": "Rochester", "state": "Minnesota", "zip": "55905", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}, {"facility": "Freeman Health System", "city": "Joplin", "state": "Missouri", "zip": "64804", "country": "United States", "geoPoint": {"lat": 37.08423, "lon": -94.51328}}, {"facility": "Truman Medical Center", "city": "Kansas City", "state": "Missouri", "zip": "64108", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "Saint Luke's Hospital of Kansas City", "city": "Kansas City", "state": "Missouri", "zip": "64111", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "Washington University", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "New York University", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "St. Francis Hospital", "city": "Roslyn", "state": "New York", "zip": "11576", "country": "United States", "geoPoint": {"lat": 40.79982, "lon": -73.65096}}, {"facility": "Duke University", "city": "Durham", "state": "North Carolina", "zip": "27705", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Eastern Nephrology Associates", "city": "New Bern", "state": "North Carolina", "zip": "28562", "country": "United States", "geoPoint": {"lat": 35.10849, "lon": -77.04411}}, {"facility": "Cleveland Clinic", "city": "Cleveland", "state": "Ohio", "zip": "44195", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "University of Pennsylvania", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19106", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Vanderbilt University", "city": "Nashville", "state": "Tennessee", "zip": "37232", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "University of Texas Southwestern", "city": "Dallas", "state": "Texas", "zip": "75390", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}]}, "referencesModule": {"references": [{"pmid": "31524498", "type": "BACKGROUND", "citation": "Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Austin B, Drazner MH, Fong MW, Givertz MM, Gordon RA, Jermyn R, Katz SD, Lamba S, Lanfear DE, LaRue SJ, Lindenfeld J, Malone M, Margulies K, Mentz RJ, Mutharasan RK, Pursley M, Umpierrez G, Kosiborod M. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation. 2019 Oct 29;140(18):1463-1476. doi: 10.1161/CIRCULATIONAHA.119.042929. Epub 2019 Sep 16."}, {"pmid": "35603596", "type": "DERIVED", "citation": "Selvaraj S, Fu Z, Jones P, Kwee LC, Windsor SL, Ilkayeva O, Newgard CB, Margulies KB, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Lanfear DE, Nassif ME, Javaheri A, Mentz RJ, Kosiborod MN, Shah SH; DEFINE-HF Investigators. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. Circulation. 2022 Sep 13;146(11):808-818. doi: 10.1161/CIRCULATIONAHA.122.060402. Epub 2022 May 23. Erratum In: Circulation. 2022 Sep 13;146(11):e167."}, {"pmid": "31081589", "type": "DERIVED", "citation": "Nassif ME, Kosiborod M. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. Diabetes Obes Metab. 2019 Apr;21 Suppl 2:19-23. doi: 10.1111/dom.13678."}], "seeAlsoLinks": [{"label": "Drug information for dapagliflozin", "url": "http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=drugportal&actionHandle=default&nextPage=jsp/drugportal/ResultScreen.jsp&TXTSUPERLISTID=0461432268&QV1=DAPAGLIFLOZIN"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Dapagliflozin", "description": "Dapagliflozin 10 mg daily\n\nDapagliflozin"}, {"id": "FG001", "title": "Dapagliflozin Matching Placebo", "description": "Dapagliflozin matching placebo 10 mg daily\n\nDapagliflozin matching placebo"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "131"}, {"groupId": "FG001", "numSubjects": "132"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "130"}, {"groupId": "FG001", "numSubjects": "131"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Dapagliflozin", "description": "Dapagliflozin 10 mg daily\n\nDapagliflozin"}, {"id": "BG001", "title": "Dapagliflozin Matching Placebo", "description": "Dapagliflozin matching placebo 10 mg daily\n\nDapagliflozin matching placebo"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "131"}, {"groupId": "BG001", "value": "132"}, {"groupId": "BG002", "value": "263"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "62.2", "spread": "11.0"}, {"groupId": "BG001", "value": "60.4", "spread": "12.0"}, {"groupId": "BG002", "value": "61.3", "spread": "11.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "70"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "95"}, {"groupId": "BG001", "value": "98"}, {"groupId": "BG002", "value": "193"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "47"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "99"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "74"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "144"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "13"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "131"}, {"groupId": "BG001", "value": "132"}, {"groupId": "BG002", "value": "263"}]}]}]}, {"title": "Duration of Heart Failure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.1", "spread": "5.8"}, {"groupId": "BG001", "value": "7.2", "spread": "6.8"}, {"groupId": "BG002", "value": "7.1", "spread": "6.3"}]}]}]}, {"title": "Previous Hospitalization for Heart Failure", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "101"}, {"groupId": "BG001", "value": "108"}, {"groupId": "BG002", "value": "209"}]}]}]}, {"title": "Time since last hospitalization for heart failure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.4", "spread": "2.3"}, {"groupId": "BG001", "value": "1.8", "spread": "3.1"}, {"groupId": "BG002", "value": "1.6", "spread": "2.7"}]}]}]}, {"title": "Ejection fraction", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "27.2", "spread": "8.0"}, {"groupId": "BG001", "value": "25.7", "spread": "8.2"}, {"groupId": "BG002", "value": "26.4", "spread": "8.1"}]}]}]}, {"title": "Ischemic heart disease", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "70"}, {"groupId": "BG001", "value": "69"}, {"groupId": "BG002", "value": "139"}]}]}]}, {"title": "Type 2 diabetes mellitus", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "81"}, {"groupId": "BG001", "value": "85"}, {"groupId": "BG002", "value": "166"}]}]}]}, {"title": "Atrial Fibrillation", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57"}, {"groupId": "BG001", "value": "49"}, {"groupId": "BG002", "value": "106"}]}]}]}, {"title": "Internal Cardiac Defibrillator (ICD)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "88"}, {"groupId": "BG001", "value": "75"}, {"groupId": "BG002", "value": "163"}]}]}]}, {"title": "Cardiac resynchronization therapy (CRT)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "68"}]}]}]}, {"title": "Angiotensin converting enzyme inhibitor (ACEI) / Angiotensin II receptor blocker (ARB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "76"}, {"groupId": "BG001", "value": "80"}, {"groupId": "BG002", "value": "156"}]}]}]}, {"title": "Angiotensin receptor-neprilysin inhibitor (ARNI)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "47"}, {"groupId": "BG001", "value": "38"}, {"groupId": "BG002", "value": "85"}]}]}]}, {"title": "\u03b2-blockers", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "130"}, {"groupId": "BG001", "value": "124"}, {"groupId": "BG002", "value": "254"}]}]}]}, {"title": "Hydralazine", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "45"}]}]}]}, {"title": "Long-acting nitrates", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "39"}]}]}]}, {"title": "Mineralocorticoid receptor agonist (MRA)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "76"}, {"groupId": "BG001", "value": "84"}, {"groupId": "BG002", "value": "160"}]}]}]}, {"title": "Loop diuretics", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "114"}, {"groupId": "BG001", "value": "111"}, {"groupId": "BG002", "value": "225"}]}]}]}, {"title": "Digoxin", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "46"}]}]}]}, {"title": "Lipid-lowering agents", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "107"}, {"groupId": "BG001", "value": "104"}, {"groupId": "BG002", "value": "211"}]}]}]}, {"title": "Anticoagulant agent", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58"}, {"groupId": "BG001", "value": "42"}, {"groupId": "BG002", "value": "100"}]}]}]}, {"title": "Insulin - among patients with type 2 diabetes", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "87"}]}]}]}, {"title": "Glucagon-like peptide-1 receptor agonist (GLP-1RA ) - among patients with type 2 diabetes", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "5"}]}]}]}, {"title": "Dipeptidyl Pepdidase 4 (DPP4) inhibitor - among patients with type 2 diabetes", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "21"}]}]}]}, {"title": "Sulfonylurea - among patients with type 2 diabetes", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "35"}]}]}]}, {"title": "Metformin - among patients with type 2 diabetes", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "62"}]}]}]}, {"title": "Body mass index", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "30.7", "lowerLimit": "27.3", "upperLimit": "35.9"}, {"groupId": "BG001", "value": "30.6", "lowerLimit": "27.6", "upperLimit": "36.4"}, {"groupId": "BG002", "value": "30.6", "lowerLimit": "27.5", "upperLimit": "36.3"}]}]}]}, {"title": "Heart rate", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "beats per minute", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "72.2", "spread": "12.4"}, {"groupId": "BG001", "value": "71.8", "spread": "11.3"}, {"groupId": "BG002", "value": "71.9", "spread": "12.3"}]}]}]}, {"title": "Systolic Blood Pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "122.3", "spread": "20.1"}, {"groupId": "BG001", "value": "124.8", "spread": "21.6"}, {"groupId": "BG002", "value": "123.7", "spread": "20.2"}]}]}]}, {"title": "N-terminal pro B-type natriuretic peptide (NT-proBNP)", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "pg/mL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1136", "lowerLimit": "668", "upperLimit": "2465"}, {"groupId": "BG001", "value": "1136", "lowerLimit": "545", "upperLimit": "2049"}, {"groupId": "BG002", "value": "1136", "lowerLimit": "615", "upperLimit": "2266"}]}]}]}, {"title": "Brain natriuretic peptide (BNP)", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "pg/mL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "288", "lowerLimit": "158", "upperLimit": "592"}, {"groupId": "BG001", "value": "242", "lowerLimit": "138", "upperLimit": "542"}, {"groupId": "BG002", "value": "269", "lowerLimit": "142", "upperLimit": "570"}]}]}]}, {"title": "Estimated glomerular filtration rate (eGFR)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/min/1.73m2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "66.9", "spread": "21.1"}, {"groupId": "BG001", "value": "71.2", "spread": "23.1"}, {"groupId": "BG002", "value": "69.1", "spread": "22.2"}]}]}]}, {"title": "Urine Albumin/Creatinine Ratio", "paramType": "MEAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "mg/g", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "19.0", "lowerLimit": "7.0", "upperLimit": "87.0"}, {"groupId": "BG001", "value": "25.0", "lowerLimit": "6.5", "upperLimit": "103.0"}, {"groupId": "BG002", "value": "22.0", "lowerLimit": "7.0", "upperLimit": "96.0"}]}]}]}, {"title": "Hemoglobin A1c", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.0", "spread": "1.8"}, {"groupId": "BG001", "value": "7.3", "spread": "2.0"}, {"groupId": "BG002", "value": "7.2", "spread": "1.9"}]}]}]}, {"title": "Hemoglobin", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "13.5", "spread": "1.9"}, {"groupId": "BG001", "value": "13.3", "spread": "1.7"}, {"groupId": "BG002", "value": "13.4", "spread": "1.8"}]}]}]}, {"title": "New York Heart Association (NYHA) Class II", "description": "New York Heart Association (NYHA) Functional Classification places patients in one of four categories based on how much they are limited during physical activity; the limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina. A higher class means a worse functional condition.\n\nNYHA Class II indicates the patient has been classified as having slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "91"}, {"groupId": "BG001", "value": "82"}, {"groupId": "BG002", "value": "173"}]}]}]}, {"title": "New York Heart Association (NYHA) Class III", "description": "New York Heart Association (NYHA) Functional Classification places patients in one of four categories based on how much they are limited during physical activity; the limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina. A higher class means a worse functional condition.\n\nNYHA Class III indicates the patient has been classified as having marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "90"}]}]}]}, {"title": "Kansas City Cardiomyopathy Questionnaire - Overall Summary Score (KCCQ-OS)", "description": "The KCCQ is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "score on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "67.4", "spread": "22.0"}, {"groupId": "BG001", "value": "67.0", "spread": "21.1"}, {"groupId": "BG002", "value": "67.2", "spread": "21.5"}]}]}]}, {"title": "Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CS)", "description": "The KCCQ is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "score on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "70.8", "spread": "21.9"}, {"groupId": "BG001", "value": "69.9", "spread": "21.4"}, {"groupId": "BG002", "value": "70.3", "spread": "21.6"}]}]}]}, {"title": "6-minute walk distance", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "meters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "306", "lowerLimit": "243", "upperLimit": "368"}, {"groupId": "BG001", "value": "305", "lowerLimit": "227", "upperLimit": "372"}, {"groupId": "BG002", "value": "305", "lowerLimit": "229", "upperLimit": "369"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Difference in the Average of the 6- and 12-week Mean N-terminal Pro B-type Natriuretic Peptide (NTproBNP).", "description": "Difference in the average of the 6- and 12-week mean N-terminal pro B-type natriuretic peptide (NTproBNP).", "populationDescription": "The number of participants analyzed may differ from the overall number of participants analyzed due to missing data at certain timepoints for some participants.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "pg/dL", "timeFrame": "Average of Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin 10 mg daily\n\nDapagliflozin"}, {"id": "OG001", "title": "Dapagliflozin Matching Placebo", "description": "Dapagliflozin matching placebo 10 mg daily\n\nDapagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "129"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1133", "lowerLimit": "1036", "upperLimit": "1238"}, {"groupId": "OG001", "value": "1191", "lowerLimit": "1089", "upperLimit": "1304"}]}]}]}, {"type": "PRIMARY", "title": "Percentage of Patients That Achieve a \u2265 5-point Increase in Heart Failure Disease Specific Quality of Life (Assessed Using Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS)) or a \u2265 20% Decrease in NTproBNP Over 12 Weeks", "description": "A composite of the percentage of patients that achieved a meaningful improvement in health status (\u22655-point increase in average of 6- and 12-week KCCQ-OS) or NT-proBNP (\u226520% decrease in average of 6- and 12-week NT-proBNP).\n\nThe KCCQ is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status. For the KCCQ overall summary score, a small but clinically meaningful change is considered to be \u2265 5 points.", "populationDescription": "The number of participants analyzed may differ from the overall number of participants analyzed due to missing data at certain timepoints for some participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "% of participants", "timeFrame": "Average of Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin 10 mg daily\n\nDapagliflozin"}, {"id": "OG001", "title": "Dapagliflozin Matching Placebo", "description": "Dapagliflozin matching placebo 10 mg daily\n\nDapagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "129"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "61.5"}, {"groupId": "OG001", "value": "50.4"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With a \u2265 5-point Increase in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS)", "description": "Percentage of patients with a \u2265 5-point increase in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) as measured at Week 6 and Week 12.\n\nThe KCCQ is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status. For the KCCQ overall summary score, a small but clinically meaningful change is considered to be \u2265 5 points.", "populationDescription": "The number of participants analyzed may differ from the overall number of participants analyzed due to missing data at certain timepoints for some participants.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline to Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin 10 mg daily\n\nDapagliflozin"}, {"id": "OG001", "title": "Dapagliflozin Matching Placebo", "description": "Dapagliflozin matching placebo 10 mg daily\n\nDapagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "129"}]}], "classes": [{"title": "Week 6 - Improvement in KCCQ-OS", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "126"}, {"groupId": "OG001", "value": "128"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "46"}]}]}, {"title": "Week 12 - Improvement in KCCQ-OS", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "126"}, {"groupId": "OG001", "value": "126"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "41"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With a \u2265 20% Decrease in N-terminal Pro B-type Natriuretic Peptide (NTproBNP)", "description": "Percentage of patients with a \u2265 20% decrease in NTproBNP as measured at Week 6 and Week 12.", "populationDescription": "The number of participants analyzed may differ from the overall number of participants analyzed due to missing data at certain timepoints for some participants.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline to Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin 10 mg daily\n\nDapagliflozin"}, {"id": "OG001", "title": "Dapagliflozin Matching Placebo", "description": "Dapagliflozin matching placebo 10 mg daily\n\nDapagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "129"}]}], "classes": [{"title": "NTproBNP decrease \u2265 20 % at Week 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "126"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "42"}]}]}, {"title": "NTproBNP decrease \u2265 20 % at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "126"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "37"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With a \u2265 5-point Increase in Kansas City Cardiomyopathy Questionnaire - Overall Summary Score (KCCQ-OS) and a \u2265 20% Decrease in N-terminal Pro B-type Natriuretic Peptide (NTproBNP)", "description": "The KCCQ is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status. For the KCCQ overall summary score, a small but clinically meaningful change is considered to be \u2265 5 points.", "populationDescription": "The number of participants analyzed may differ from the overall number of participants analyzed due to missing data at certain timepoints for some participants.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Average of Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin 10 mg daily\n\nDapagliflozin"}, {"id": "OG001", "title": "Dapagliflozin Matching Placebo", "description": "Dapagliflozin matching placebo 10 mg daily\n\nDapagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "129"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "17"}]}]}]}, {"type": "SECONDARY", "title": "Change in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) Over 12 Weeks.", "description": "Change in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) over 12 weeks as measured at Week 6 and Week 12.The KCCQ is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status. For the KCCQ overall summary score, a small but clinically meaningful change is considered to be \u2265 5 points.", "populationDescription": "The number of participants analyzed may differ from the overall number of participants analyzed due to missing data at certain timepoints for some participants.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline to Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin 10 mg daily\n\nDapagliflozin"}, {"id": "OG001", "title": "Dapagliflozin Matching Placebo", "description": "Dapagliflozin matching placebo 10 mg daily\n\nDapagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "129"}]}], "classes": [{"title": "KCCQ-OS - week 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "126"}, {"groupId": "OG001", "value": "128"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "71.1", "lowerLimit": "68.7", "upperLimit": "73.5"}, {"groupId": "OG001", "value": "70.1", "lowerLimit": "67.7", "upperLimit": "72.5"}]}]}, {"title": "KCCQ-OS - week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "126"}, {"groupId": "OG001", "value": "126"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "72.6", "lowerLimit": "70.2", "upperLimit": "75.0"}, {"groupId": "OG001", "value": "68.9", "lowerLimit": "66.5", "upperLimit": "71.4"}]}]}]}, {"type": "SECONDARY", "title": "Change in 6 Minute Walk Score Over 12 Weeks.", "description": "Change in 6 minute walk score over 12 weeks as measured at Week 6 and Week 12. The 6 minute walk test measures the distance in meters that a patient can quickly walk on a flat, hard surface in a period of 6 minutes.", "populationDescription": "The number of participants analyzed may differ from the overall number of participants analyzed due to missing data at certain timepoints for some participants.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "meters", "timeFrame": "Baseline to Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin 10 mg daily\n\nDapagliflozin"}, {"id": "OG001", "title": "Dapagliflozin Matching Placebo", "description": "Dapagliflozin matching placebo 10 mg daily\n\nDapagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "129"}]}], "classes": [{"title": "6-minute walk distance - 6 weeks", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "126"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "297.1", "lowerLimit": "285.1", "upperLimit": "309.6"}, {"groupId": "OG001", "value": "289.6", "lowerLimit": "278.0", "upperLimit": "301.7"}]}]}, {"title": "6-minute walk distance - 12 weeks", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "117"}, {"groupId": "OG001", "value": "123"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "303.7", "lowerLimit": "291.2", "upperLimit": "316.7"}, {"groupId": "OG001", "value": "301.3", "lowerLimit": "289.1", "upperLimit": "313.9"}]}]}]}, {"type": "SECONDARY", "title": "Change in Brain Natriuretic Peptide (BNP) Over 12 Weeks.", "description": "Change in BNP over 12 weeks as measured at Week 6 and Week 12 as measured at Week 6 and Week 12.", "populationDescription": "The number of participants analyzed may differ from the overall number of participants analyzed due to missing data at certain timepoints for some participants.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline to Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin 10 mg daily\n\nDapagliflozin"}, {"id": "OG001", "title": "Dapagliflozin Matching Placebo", "description": "Dapagliflozin matching placebo 10 mg daily\n\nDapagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "129"}]}], "classes": [{"title": "BNP - week 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "124"}, {"groupId": "OG001", "value": "127"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "236", "lowerLimit": "212", "upperLimit": "263"}, {"groupId": "OG001", "value": "265", "lowerLimit": "238", "upperLimit": "296"}]}]}, {"title": "BNP - week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "124"}, {"groupId": "OG001", "value": "124"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "228", "lowerLimit": "204", "upperLimit": "254"}, {"groupId": "OG001", "value": "272", "lowerLimit": "243", "upperLimit": "303"}]}]}]}, {"type": "SECONDARY", "title": "Change in Hemoglobin A1c (HbA1c) Over 12 Weeks.", "description": "Change in HbA1c over 12 weeks as measured at Week 6 and Week 12.", "populationDescription": "The number analyzed may differ from the overall number analyzed due to missing data at certain timepoints for some participants.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of glycated hemoglobin", "timeFrame": "Baseline to Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin 10 mg daily\n\nDapagliflozin"}, {"id": "OG001", "title": "Dapagliflozin Matching Placebo", "description": "Dapagliflozin matching placebo 10 mg daily\n\nDapagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "129"}]}], "classes": [{"title": "HbA1c - week 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "127"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.9", "lowerLimit": "6.8", "upperLimit": "7.1"}, {"groupId": "OG001", "value": "7.1", "lowerLimit": "7.0", "upperLimit": "7.2"}]}]}, {"title": "HbA1c - week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "126"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.9", "lowerLimit": "6.8", "upperLimit": "7.1"}, {"groupId": "OG001", "value": "7.1", "lowerLimit": "7.0", "upperLimit": "7.2"}]}]}]}, {"type": "SECONDARY", "title": "Change in Weight Over 12 Weeks", "description": "Change in weight over 12 weeks as measured at Week 6 and Week 12.", "populationDescription": "The number of participants analyzed may differ from the overall number of participants analyzed due to missing data at certain timepoints for some participants.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "kg", "timeFrame": "Baseline to Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin 10 mg daily\n\nDapagliflozin"}, {"id": "OG001", "title": "Dapagliflozin Matching Placebo", "description": "Dapagliflozin matching placebo 10 mg daily\n\nDapagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "129"}]}], "classes": [{"title": "Weight - week 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "127"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "96.0", "lowerLimit": "95.4", "upperLimit": "96.5"}, {"groupId": "OG001", "value": "96.6", "lowerLimit": "96.0", "upperLimit": "97.1"}]}]}, {"title": "Weight - week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "126"}, {"groupId": "OG001", "value": "128"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "96.3", "lowerLimit": "95.7", "upperLimit": "96.8"}, {"groupId": "OG001", "value": "96.6", "lowerLimit": "96.0", "upperLimit": "97.1"}]}]}]}, {"type": "SECONDARY", "title": "Change in Systolic Blood Pressure Over 12 Weeks", "description": "Change in systolic blood pressure over 12 weeks as measured at Week 6 and Week 12.", "populationDescription": "The number of participants analyzed may differ from the overall number of participants analyzed due to missing data at certain timepoints for some participants.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Dapagliflozin", "description": "Dapagliflozin 10 mg daily\n\nDapagliflozin"}, {"id": "OG001", "title": "Dapagliflozin Matching Placebo", "description": "Dapagliflozin matching placebo 10 mg daily\n\nDapagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "129"}]}], "classes": [{"title": "Systolic Blood Pressure - week 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "127"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "119.2", "lowerLimit": "116.6", "upperLimit": "121.9"}, {"groupId": "OG001", "value": "121.1", "lowerLimit": "118.5", "upperLimit": "122.4"}]}]}, {"title": "Systolic Blood Pressure - week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "126"}, {"groupId": "OG001", "value": "128"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "120.9", "lowerLimit": "118.2", "upperLimit": "123.5"}, {"groupId": "OG001", "value": "119.8", "lowerLimit": "117.2", "upperLimit": "122.4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse events were collected for up to 15 weeks. The adverse event collection period started at the time the patient signed consent at their Screening Visit, continued through a 12-week double-blind treatment period after randomization, and ended after completion of a 1-week follow-up period after completion of the double-blind treatment period.", "description": "Serious Adverse Events, Drug Adverse Events, Adverse Events of Special Interest and Urgent Outpatient Heart Failure Visits were collected. A Drug Adverse Event is an adverse event which leads to premature and permanent discontinuation of study medication. Adverse Events of Special Interest include diabetic ketoacidosis, volume depletion (defined as hypotension, syncope, orthostatic hypotension or dehydration), severe hypoglycemic events and lower limb amputations.", "eventGroups": [{"id": "EG000", "title": "Dapagliflozin", "description": "Dapagliflozin 10 mg daily\n\nDapagliflozin", "deathsNumAffected": 1, "deathsNumAtRisk": 131, "seriousNumAffected": 32, "seriousNumAtRisk": 131, "otherNumAffected": 19, "otherNumAtRisk": 131}, {"id": "EG001", "title": "Dapagliflozin Matching Placebo", "description": "Dapagliflozin matching placebo 10 mg daily\n\nDapagliflozin matching placebo", "deathsNumAffected": 1, "deathsNumAtRisk": 132, "seriousNumAffected": 31, "seriousNumAtRisk": 132, "otherNumAffected": 18, "otherNumAtRisk": 132}], "seriousEvents": [{"term": "Exacerbation of Heart Failure", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 26, "numAffected": 14, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 19, "numAffected": 14, "numAtRisk": 132}]}, {"term": "Abdominal Pain", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Acute Dyspnea", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Acute Kidney Injury", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Acute Respiratory Distress", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Acute Respiratory Failure", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Anemia", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Atrial Fibrillation", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Atypical Chest Pain", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Cachexia", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Cardiogenic Shock", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Cardiomyopathy", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Cerebrovascular Accident", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 132}]}, {"term": "Chest Pain", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 6, "numAffected": 4, "numAtRisk": 132}]}, {"term": "Cirrhosis", "organSystem": "Hepatobiliary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Cocaine Abuse", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Elevated Cardiac Enzymes", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Epistaxis", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Exacerbation of COPD", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Gastroenteritis", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 132}]}, {"term": "Gout", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Herpes Zoster", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Hypertensive Urgency", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "ICD Implantation", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 132}]}, {"term": "ICD Shock due to Atrial Fibrillation", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Left Great Toe Infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Morbid Obesity - Remove Laparoscopic band", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Myeloma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Non Intractable Headache", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Myocardial Infarction", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 132}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Pre-Renal Acute Kidney Injury", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Septic shock secondary to purulent skin infection from herpes zoster", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Sudden Death", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Syncope", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Transient Ischemic Attack", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Urinary Tract Infection", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Ventricular Arrhythmia", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 132}]}, {"term": "Upper Respiratory Infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Volume Depletion", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Worsening Coronary Artery Disease", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Worsening Peripheral Artery Disease", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Oliguric Acute Kidney Injury on CKD III", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}], "otherEvents": [{"term": "Urgent Heart Failure Visit", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 12, "numAffected": 7, "numAtRisk": 132}]}, {"term": "Volume Depletion", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 10, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 132}]}, {"term": "Severe Hypoglycemia", "organSystem": "Endocrine disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Hypotension", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Syncope", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Urinary Tract Infection", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Vaginal Discharge", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}, {"term": "Bullae", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 132}]}, {"term": "Atypical Chest Pain", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 132}]}, {"term": "Headache", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 131}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 132}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Program Manager, Cardiometabolic Research", "organization": "Saint Luke's Hospital of Kansas City", "email": "DEFINE-HF@saint-lukes.org", "phone": "8166957561"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-11-04", "uploadDate": "2021-09-10T18:17", "filename": "Prot_000.pdf", "size": 2485247}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2019-06-26", "uploadDate": "2021-09-10T18:22", "filename": "SAP_001.pdf", "size": 1437094}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000529054", "term": "Dapagliflozin"}], "ancestors": [{"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M348449", "name": "Dapagliflozin", "asFound": "Intramuscular", "relevance": "HIGH"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}